Richard W Joseph1, Payal Kapur2, Daniel J Serie2, Mansi Parasramka2, Thai H Ho2, John C Cheville2, Eugene Frenkel2, Alexander S Parker2, James Brugarolas3. 1. Division of Medical Oncology, Departments of Health Sciences Research and Medicine and Division of Cancer Biology, Mayo Clinic Florida, Jacksonville, Florida; Department of Pathology, Kidney Cancer Program, Simmons Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Internal Medicine and Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, Minnesota; Division of Medical Oncology, Mayo Clinic Arizona, Phoenix, Arizona. Electronic address: joseph.richard@mayo.edu. 2. Division of Medical Oncology, Departments of Health Sciences Research and Medicine and Division of Cancer Biology, Mayo Clinic Florida, Jacksonville, Florida; Department of Pathology, Kidney Cancer Program, Simmons Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Internal Medicine and Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, Minnesota; Division of Medical Oncology, Mayo Clinic Arizona, Phoenix, Arizona. 3. Division of Medical Oncology, Departments of Health Sciences Research and Medicine and Division of Cancer Biology, Mayo Clinic Florida, Jacksonville, Florida; Department of Pathology, Kidney Cancer Program, Simmons Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Internal Medicine and Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, Minnesota; Division of Medical Oncology, Mayo Clinic Arizona, Phoenix, Arizona. Electronic address: james.brugarolas@utsouthwestern.edu.
Abstract
PURPOSE: In clear cell renal cell carcinoma BAP1 and PBRM1 are 2 of the most commonly mutated genes (10% to 15% and 40% to 50%, respectively). We sought to determine the prognostic significance of PBRM1 and BAP1 expression in clear cell renal cell carcinoma. MATERIALS AND METHODS: We used immunohistochemistry to assess PBRM1 protein expression in 1,479 primary clear cell renal cell carcinoma tumors that were previously stained for BAP1. A centralized pathologist reviewed all cases and categorized tumors as positive or deficient for PBRM1 and BAP1. Kaplan-Meier and Cox regression models were used to evaluate association of PBRM1 and BAP1 expression with the risk of death from renal cell carcinoma and the risk of metastasis after adjustment for age and the Mayo Clinic SSIGN (stage, size, grade and necrosis) score. RESULTS: PBRM1 and BAP1 expression was PBRM1+ BAP1+ in 40.1% of tumors, PBRM1- BAP1+ in 48.6%, PBRM1+ BAP1- in 8.7% and PBRM1- BAP1- in 1.8%. The incidence of PBRM1 and BAP1 loss in the same tumor was significantly lower than expected (actual 1.8% vs expected 5.3%, p <0.0001). Compared to patients with PBRM1+ BAP1+ tumors those with PBRM1- BAP1+ lesions were more likely to die of renal cell carcinoma (HR 1.39, p = 0.035), followed by those with PBRM1+ BAP1- and PBRM1- BAP1- tumors (HR 3.25 and 5.2, respectively, each p <0.001). PBRM1 and BAP1 expression did not add independent prognostic information to the SSIGN score. CONCLUSIONS: PBRM1 and BAP1 expression identified 4 clinical subgroups of patients with clear cell renal cell carcinoma who had divergent clinical outcomes. The clinical value of these biomarkers will be fully realized when therapies targeting pathways downstream of PBRM1 and BAP1 are developed.
PURPOSE: In clear cell renal cell carcinomaBAP1 and PBRM1 are 2 of the most commonly mutated genes (10% to 15% and 40% to 50%, respectively). We sought to determine the prognostic significance of PBRM1 and BAP1 expression in clear cell renal cell carcinoma. MATERIALS AND METHODS: We used immunohistochemistry to assess PBRM1 protein expression in 1,479 primary clear cell renal cell carcinoma tumors that were previously stained for BAP1. A centralized pathologist reviewed all cases and categorized tumors as positive or deficient for PBRM1 and BAP1. Kaplan-Meier and Cox regression models were used to evaluate association of PBRM1 and BAP1 expression with the risk of death from renal cell carcinoma and the risk of metastasis after adjustment for age and the Mayo Clinic SSIGN (stage, size, grade and necrosis) score. RESULTS:PBRM1 and BAP1 expression was PBRM1+ BAP1+ in 40.1% of tumors, PBRM1- BAP1+ in 48.6%, PBRM1+ BAP1- in 8.7% and PBRM1- BAP1- in 1.8%. The incidence of PBRM1 and BAP1 loss in the same tumor was significantly lower than expected (actual 1.8% vs expected 5.3%, p <0.0001). Compared to patients with PBRM1+ BAP1+ tumors those with PBRM1- BAP1+ lesions were more likely to die of renal cell carcinoma (HR 1.39, p = 0.035), followed by those with PBRM1+ BAP1- and PBRM1- BAP1- tumors (HR 3.25 and 5.2, respectively, each p <0.001). PBRM1 and BAP1 expression did not add independent prognostic information to the SSIGN score. CONCLUSIONS:PBRM1 and BAP1 expression identified 4 clinical subgroups of patients with clear cell renal cell carcinoma who had divergent clinical outcomes. The clinical value of these biomarkers will be fully realized when therapies targeting pathways downstream of PBRM1 and BAP1 are developed.
Authors: Walter H da Costa; Mariana Rezende; Felipe C Carneiro; Rafael M Rocha; Isabela W da Cunha; Dirce M Carraro; Gustavo C Guimaraes; Stenio de Cassio Zequi Journal: BJU Int Date: 2013-12-02 Impact factor: 5.588
Authors: Alexander S Parker; Jeanette E Eckel-Passow; Daniel Serie; Tracy Hilton; Mansi Parasramka; Richard W Joseph; Kevin J Wu; John C Cheville; Bradley C Leibovich Journal: Eur Urol Date: 2013-12-25 Impact factor: 20.096
Authors: Richard W Joseph; Payal Kapur; Daniel J Serie; Jeanette E Eckel-Passow; Mansi Parasramka; Thai Ho; John C Cheville; Eugene Frenkel; Dinesh Rakheja; James Brugarolas; Alexander Parker Journal: Cancer Date: 2013-12-30 Impact factor: 6.860
Authors: A Ari Hakimi; Irina Ostrovnaya; Boris Reva; Nikolaus Schultz; Ying-Bei Chen; Mithat Gonen; Han Liu; Shugaku Takeda; Martin H Voss; Satish K Tickoo; Victor E Reuter; Paul Russo; Emily H Cheng; Chris Sander; Robert J Motzer; James J Hsieh Journal: Clin Cancer Res Date: 2013-04-25 Impact factor: 12.531
Authors: Samuel Peña-Llopis; Silvia Vega-Rubín-de-Celis; Arnold Liao; Nan Leng; Andrea Pavía-Jiménez; Shanshan Wang; Toshinari Yamasaki; Leah Zhrebker; Sharanya Sivanand; Patrick Spence; Lisa Kinch; Tina Hambuch; Suneer Jain; Yair Lotan; Vitaly Margulis; Arthur I Sagalowsky; Pia Banerji Summerour; Wareef Kabbani; S W Wendy Wong; Nick Grishin; Marc Laurent; Xian-Jin Xie; Christian D Haudenschild; Mark T Ross; David R Bentley; Payal Kapur; James Brugarolas Journal: Nat Genet Date: 2012-06-10 Impact factor: 38.330
Authors: Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2010-01-06 Impact factor: 49.962
Authors: Daniel M Tennenbaum; Brandon J Manley; Emily Zabor; Maria F Becerra; Maria I Carlo; Jozefina Casuscelli; Almedina Redzematovic; Nabeela Khan; Maria E Arcila; Martin H Voss; Darren R Feldman; Robert J Motzer; Nicole E Benfante; Jonathan A Coleman; Paul Russo; James J Hsieh; Abraham Ari Hakimi Journal: Urol Oncol Date: 2017-04-10 Impact factor: 3.498
Authors: A Ari Hakimi; Martin H Voss; Fengshen Kuo; Alejandro Sanchez; Ming Liu; Briana G Nixon; Lynda Vuong; Irina Ostrovnaya; Ying-Bei Chen; Victor Reuter; Nadeem Riaz; Yuan Cheng; Parul Patel; Mahtab Marker; Albert Reising; Ming O Li; Timothy A Chan; Robert J Motzer Journal: Cancer Discov Date: 2019-01-08 Impact factor: 39.397
Authors: Yi-Feng Gu; Shannon Cohn; Alana Christie; Tiffani McKenzie; Nicholas Wolff; Quyen N Do; Ananth J Madhuranthakam; Ivan Pedrosa; Tao Wang; Anwesha Dey; Meinrad Busslinger; Xian-Jin Xie; Robert E Hammer; Renée M McKay; Payal Kapur; James Brugarolas Journal: Cancer Discov Date: 2017-05-04 Impact factor: 39.397
Authors: Brandon John Manley; Emily C Zabor; Jozefina Casuscelli; Daniel M Tennenbaum; Almedina Redzematovic; Maria F Becerra; Nicole Benfante; Yusuke Sato; Teppei Morikawa; Haruki Kume; Masashi Fukayama; Yukio Homma; Seishi Ogawa; Maria E Arcila; Martin H Voss; Darren R Feldman; Jonathan A Coleman; Victor E Reuter; Robert J Motzer; Paul Russo; James J Hsieh; A Ari Hakimi Journal: Eur Urol Focus Date: 2016-07-16
Authors: Martin H Voss; Albert Reising; Yuan Cheng; Parul Patel; Mahtab Marker; Fengshen Kuo; Timothy A Chan; Toni K Choueiri; James J Hsieh; A Ari Hakimi; Robert J Motzer Journal: Lancet Oncol Date: 2018-11-08 Impact factor: 41.316
Authors: James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer Journal: Eur Urol Date: 2016-10-15 Impact factor: 20.096